Medicare Enrolled
Dr. Rajeev Kulkarni, MD
Hematology & Oncology · Troy, OH
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kulkarni from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kulkarni?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kulkarni
Dr. Rajeev Kulkarni is a hematology & oncology specialist in Troy, OH, with 19 years of NPI registration. Based on federal Medicare data, Dr. Kulkarni performed 116,369 Medicare services across 1,407 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kulkarni received a total of $9,556 from 74 pharmaceutical and/or device companies across 428 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kulkarni is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 3% volume in OH
$9,556 industry payments
Medicare Practice Summary
Medicare Utilization ↗116,369
Medicare services
Top 3% in OH for hematology & oncology
1,407
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~6,125 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
56,000 | $0 | $0 |
| Pembrolizumab injection (Keytruda) | 28,400 | $43 | $99 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
16,200 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 7,980 | $19 | $37 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,808 | $0 | $0 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,260 | $85 | $207 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,220 | $1 | $3 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
841 | $128 | $281 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
488 | $93 | $403 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
358 | $45 | $181 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
295 | $11 | $64 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
283 | $10 | $45 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
255 | $53 | $155 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
149 | $21 | $100 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
105 | $47 | $198 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
102 | $91 | $156 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
94 | $41 | $166 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
94 | $21 | $92 |
| New patient office visit, complex (60-74 min) | 91 | $159 | $402 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
90 | $1 | $1 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
68 | $2 | $5 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
63 | $24 | $148 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
42 | $126 | $338 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
38 | $9 | $37 |
| Transitional care management, high complexity Coordination of care for a patient transitioning from a short-term hospital stay or other facility to home or another care setting. This service addresses a high-complexity medical problem. |
33 | $206 | $448 |
| Transitional care management services, moderate complexity Services provided to coordinate care during the transition from an inpatient or other facility setting back to the community. This includes follow-up and management of a health problem of at least moderate complexity. |
12 | $154 | $318 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.1% high complexity
96.9% medium
2.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$9,556
Total received (2018-2024)
Avg $1,365/year across 7 years
Top 29% in OH for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
74
Companies
428
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,894 (82.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,476 (15.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$185 (1.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,601
2023
$2,340
2022
$1,440
2021
$1,012
2020
$113
2019
$681
2018
$1,368
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$242
ABBVIE INC.
$238
Daiichi Sankyo Inc.
$222
AstraZeneca Pharmaceuticals LP
$183
PFIZER INC.
$151
Janssen Biotech, Inc.
$149
Regeneron Healthcare Solutions, Inc.
$142
EMD Serono, Inc.
$116
Celgene Corporation
$108
Alexion Pharmaceuticals, Inc.
$83
Astellas Pharma US Inc
$75
Adaptive Biotechnologies Corporation
$70
Gilead Sciences, Inc.
$63
GlaxoSmithKline, LLC.
$63
Genmab U.S., Inc.
$48
Merck Sharp & Dohme LLC
$45
Takeda Pharmaceuticals U.S.A., Inc.
$42
SpringWorks Therapeutics, Inc.
$42
Incyte Corporation
$40
Eisai Inc.
$39
Blueprint Medicines Corporation
$35
TerSera Therapeutics LLC
$31
Amneal Pharmaceuticals LLC
$31
ARRAY BIOPHARMA INC
$30
Aveo Pharmaceuticals, Inc.
$28
TAIHO ONCOLOGY, INC.
$27
Bayer Healthcare Pharmaceuticals Inc.
$27
Ipsen Biopharmaceuticals, Inc
$25
GENZYME CORPORATION
$23
E.R. Squibb & Sons, L.L.C.
$23
JAZZ PHARMACEUTICALS INC.
$21
PharmaEssentia USA Corporation
$21
Fennec Pharmaceuticals, Inc.
$19
Tempus AI, Inc
$19
BeiGene USA, Inc.
$18
Cumberland Pharmaceuticals, Inc.
$18
Alnylam Pharmaceuticals Inc.
$16
Agios Pharmaceuticals, Inc.
$14
Exelixis Inc.
$13
Top 3 companies account for 27.0% of 2024 payments
All-time payments by company (2018-2024) ›
Seattle Genetics, Inc.
$976
PFIZER INC.
$702
Novartis Pharmaceuticals Corporation
$702
EMD Serono, Inc.
$655
Janssen Biotech, Inc.
$597
AstraZeneca Pharmaceuticals LP
$428
Pharmacyclics LLC, An AbbVie Company
$378
E.R. Squibb & Sons, L.L.C.
$329
Daiichi Sankyo Inc.
$303
ABBVIE INC.
$280
Celgene Corporation
$247
Amgen Inc.
$244
Regeneron Healthcare Solutions, Inc.
$230
Astellas Pharma US Inc
$211
GENZYME CORPORATION
$200
Merck Sharp & Dohme LLC
$172
Seagen Inc.
$168
GlaxoSmithKline, LLC.
$157
Bayer Healthcare Pharmaceuticals Inc.
$143
Rigel Pharmaceuticals, Inc.
$133
Incyte Corporation
$123
EISAI INC.
$116
Gilead Sciences, Inc.
$115
JAZZ PHARMACEUTICALS INC.
$106
BeiGene USA, Inc.
$105
Bayer HealthCare Pharmaceuticals Inc.
$87
Alexion Pharmaceuticals, Inc.
$83
Takeda Pharmaceuticals U.S.A., Inc.
$83
ARRAY BIOPHARMA INC
$81
Genmab U.S., Inc.
$76
TerSera Therapeutics LLC
$75
Genentech USA, Inc.
$74
Adaptive Biotechnologies Corporation
$70
Eisai Inc.
$62
Pharmacyclics LLC, an AbbVie Company
$62
Foundation Medicine, Inc.
$47
Aveo Pharmaceuticals, Inc.
$46
Merck Sharp & Dohme Corporation
$43
SpringWorks Therapeutics, Inc.
$42
PharmaEssentia USA Corporation
$42
SERVIER PHARMACEUTICALS LLC
$41
AVEO Pharmaceuticals, Inc.
$41
Acceleron Pharma, Inc.
$38
Stemline Therapeutics Inc.
$38
Blueprint Medicines Corporation
$35
Taiho Oncology, Inc.
$34
Karyopharm Therapeutics Inc.
$34
Exelixis Inc.
$31
Amneal Pharmaceuticals LLC
$31
Deciphera Pharmaceuticals Inc.
$29
TAIHO ONCOLOGY, INC.
$27
Lilly USA, LLC
$27
Cardinal Health 108, LLC
$26
Ipsen Biopharmaceuticals, Inc
$25
Fresenius Kabi USA, LLC
$25
Janssen Scientific Affairs, LLC
$24
Fennec Pharmaceuticals, Inc.
$19
Tempus AI, Inc
$19
Cumberland Pharmaceuticals, Inc.
$18
Sun Pharmaceutical Industries Inc.
$18
Apellis Pharmaceuticals, Inc.
$18
Alnylam Pharmaceuticals Inc.
$16
Boehringer Ingelheim Pharmaceuticals, Inc.
$14
Kyowa Kirin, Inc.
$14
NOVARTIS PHARMACEUTICALS CORPORATION
$14
Agios Pharmaceuticals, Inc.
$14
CTI BioPharma Corp.
$13
ADC Therapeutics America, Inc.
$13
Epizyme, Inc.,
$12
Clovis Oncology, Inc.
$12
PUMA BIOTECHNOLOGY, INC.
$11
SUN PHARMACEUTICAL INDUSTRIES INC.
$11
Janssen Pharmaceuticals, Inc
$10
Secura Bio, Inc.
$10
Top 3 companies account for 24.9% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AUGTYRO · AVASTIN · AYVAKIT · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · CABLIVI · CABOMETYX · CALQUENCE · DARZALEX · ELIQUIS · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · EXKIVITY · Empaveli · Enhertu · Epkinly · FARYDAK · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · GILOTRIF · GIVLAARI · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUMOXITI · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · MYLOTARG · NERLYNX · Nplate · Nubeqa · OGSIVEO · OJJAARA · OPDIVO · OPDUALAG · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PYRUKYND · Padcev · Pedmark · Phesgo · Polivy · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RYBREVANT · Reblozyl · Rezlidhia · Rubraca · SANCUSO · SANDOSTATIN · SANDOSTATIN LAR · SCEMBLIX · SHINGRIX · Stimufend · Stivarga · TABRECTA · TASIGNA · TAZVERIK · TECVAYLI · TEPMETKO · TIBSOVO · TUKYSA · Tavalisse · Tepmetko · Tibsovo · Tivdak · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · Vectibix · Venclexta · Vonjo · Vyloy · XALKORI · XARELTO · XPOVIO · XT CDX · XTANDI · Xermelo · Xtandi · YONSA · ZEPZELCA · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (83%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
31
Per 100K population
28.3
County median income
$74,175
Nearest hospital
UPPER VALLEY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kulkarni is a mixed practice specialist, with above-average Medicare volume (top 3% in OH), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kulkarni experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Kulkarni performed 56,000 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kulkarni receive payments from pharmaceutical companies?
Yes. Dr. Kulkarni received a total of $9,556 from 74 companies across 428 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kulkarni's costs compare to other hematology & oncology specialists in Troy?
Dr. Kulkarni's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kulkarni) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Troy
Browse hematology & oncology specialists in Troy ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in OH
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in OH
Which OH hematology & oncology specialists receive the most from drug and device companies.
By company
Seattle Genetics, Inc. Payments to Doctors
See all physicians who received payments from Seattle Genetics, Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology